Literature DB >> 7697731

Therapeutic effect of early thymic irradiation in (NZB x NZW)F1 mice, associated with a selective decrease in the levels of IgG3 and gp70-anti-gp70 immune complexes.

C Erausquin1, R Merino, S Izui, L Fernandez-Sueiro, F Saez, F Fernandez, V Rodriguez-Valverde, J Merino.   

Abstract

The lupus-prone (NZB x NZW)F1 female mice (NZB/W) develop an autoimmune disease characterized by production of autoAb and fatal glomerulonephritis. Since it has been previously shown that total lymphoid irradiation has a beneficial effect in this model, we have analyzed whether early thymic irradiation (ETI) could improve the course of the lupus-like syndrome in these mice. NZB/W mice received thymic irradiation (4500 rads) beginning at 10 weeks of age, prior to the onset of autoimmune manifestations. Then, they were evaluated for survival, renal histology, and serological markers of autoimmunity, in comparison to nonirradiated NZB/W females. The treatment with ETI improved nephritis and survival in NZB/W mice: 50% mortality was observed at 12 months in irradiated mice and at 9 months in untreated mice. This improved survival could not be attributed to a reduction in the titers of anti-dsDNA Ab nor in the levels of total immune complexes which were essentially identical in both groups. By contrast, this improvement was related to a selective normalization in the serum levels of IgG3 and gp70-anti-gp70 immune complexes (gp70IC) in ETI NZB/W female mice as compared to that seen in nonirradiated NZB/W females. These data show the therapeutical effect of ETI and support the pathogenic role of IgG3 and gp70IC in the development of glomerulonephritis in NZB/W mice.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7697731     DOI: 10.1006/cimm.1995.1028

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  8 in total

1.  Prevention of systemic lupus erythematosus-like disease in (NZBxNZW)F1 mice by treating with CDR1- and CDR3-based peptides of a pathogenic autoantibody.

Authors:  E Eilat; H Zinger; A Nyska; E Mozes
Journal:  J Clin Immunol       Date:  2000-07       Impact factor: 8.317

2.  The mechanism by which a peptide based on complementarity-determining region-1 of a pathogenic anti-DNA auto-Ab ameliorates experimental systemic lupus erythematosus.

Authors:  E Eilat; M Dayan; H Zinger; E Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

3.  Genetic linkage of IgG autoantibody production in relation to lupus nephritis in New Zealand hybrid mice.

Authors:  T J Vyse; C G Drake; S J Rozzo; E Roper; S Izui; B L Kotzin
Journal:  J Clin Invest       Date:  1996-10-15       Impact factor: 14.808

4.  Spontaneous autoimmune disease in (NZB x NZW)F1 mice is ameliorated by treatment with methimazole.

Authors:  E Mozes; H Zinger; L D Kohn; D S Singer
Journal:  J Clin Immunol       Date:  1998-03       Impact factor: 8.317

5.  Imbalance towards Th1 predominance is associated with acceleration of lupus-like autoimmune syndrome in MRL mice.

Authors:  S Takahashi; L Fossati; M Iwamoto; R Merino; R Motta; T Kobayakawa; S Izui
Journal:  J Clin Invest       Date:  1996-04-01       Impact factor: 14.808

6.  Beneficial effects of the anti-oestrogen tamoxifen on systemic lupus erythematosus of (NZBxNZW)F1 female mice are associated with specific reduction of IgG3 autoantibodies.

Authors:  Z M Sthoeger; H Zinger; E Mozes
Journal:  Ann Rheum Dis       Date:  2003-04       Impact factor: 19.103

7.  IgG3 deficiency extends lifespan and attenuates progression of glomerulonephritis in MRL/lpr mice.

Authors:  Neil S Greenspan; Myro A Lu; Jacob W Shipley; Xuedong Ding; Qing Li; Dilara Sultana; Maria Kollaros; John R Schreiber; Pingfu Fu; Chaim Putterman; Steven N Emancipator
Journal:  Biol Direct       Date:  2012-01-16       Impact factor: 4.540

8.  Interleukin-4 protects against a genetically linked lupus-like autoimmune syndrome.

Authors:  M L Santiago; L Fossati; C Jacquet; W Müller; S Izui; L Reininger
Journal:  J Exp Med       Date:  1997-01-06       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.